Abstract: The present invention relates to the stimulation of the IL-15Rbeta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.

Abstract: A process is provided for inhibiting symptoms of intestinal dysbiosis in a subject that includes the oral administration to the subject suffering from intestinal dysbiosis an IgA, IgM, or a combination thereof. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of intestinal dysbiosis in that subject are inhibited. Even non-secretory forms of IgA or IgM are effective when administered orally.

Abstract: Provided are human antibodies that specifically bind to HBV Pre-S1 domain ligand and inhibit HBV or HDV infection, antibodies binding to a set of amino acid residues that are critical for viral receptor engagement, and uses of these antibodies to prevent, or treat or diagnose HBV or HDV infection.

Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.

Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.

Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (C1fA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.

Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.

Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.

Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: The present disclosure provides immunotherapeutic compositions and methods for enhancing an immune response and for treating cancer or inflammatory conditions mediated by autoreactive B cells in a subject. In some aspects, multispecific antigen-binding constructs are provided that recognize at least one tumor antigen or B-lineage cell antigen and NKp30 and/or another activating NK receptor. In some aspects, multispecific antigen-binding constructs are provided that recognize at least two tumor antigens or two antigens expressed by B-lineage cells, NKp30, and another activating NK receptor. The multispecific antigen-binding constructs and methods disclosed herein can be used for the treatment of cancer, even a cancer characterized by a CD16 deficient microenvironment and/or characterized by target cells (e.g., cancer cells) having a low level of expression of the tumor antigen.

Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.

Abstract: Provided are methods and composition useful in isolating or otherwise preparing a population of target cells. In part, it relates to recombinant antibodies comprising an exogenous proteolytic cleavage site and nucleic acid molecules encoding the antibodies.

Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.

Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

Abstract: The presently disclosed subject matter relates to methods and compositions for determining synapse formation, e.g., synapse formation associated with the activity of multispecific antibodies such as T cell-dependent bispecific antibodies.

Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.

Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.

Abstract: Provided are compositions and methods for treating or ameliorating a cancer by targeting cell surface-expressed ALPHA-V BETA-3 polypeptides in Cancer Stem Cells (CSCs) to kill the CSCs, to treat cancers caused or initiated by cancer or tumor 10 cells, or Cancer Stem Cells (CSCs), expressing ALPHA-V BETA-3 polypeptides on their cell surfaces. Provided are compositions and methods for targeting and killing ALPHA-V BETA-3-positive Cancer Stem Cells (CSCs) and treating drug resistant cancers. In alternative embodiments, compositions and methods as provided herein use an antibody that can specifically bind to human ALPHA-V BETA-3 that also comprises an Fc portion that can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) killing of cancer cells by macrophages; for example, use a humanized antibody to ALPHA-V BETA-3 that has been modified to include an engineered Fc portion that specifically binds to human macrophages.

Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.

Abstract: Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition (e.g., cancer) by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.

Abstract: In certain embodiments, the disclosure provides an IgG4 antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises: (a) a modified IgG4 CH1 region having a substitution of the lysine residue at position 196; or (b) a modified IgG4 hinge region having a substitution of the serine residue at position 217, the glycine residue at position 220, the proline residue at position 224 or the proline residue at position 225. Preferably, the IgG4 antibody further comprises a substitution of the serine residue at position 228 in the heavy chain hinge region.

Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

Abstract: Chimeric antigen receptors containing CD19/CD20 or CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Abstract: Novel compounds which bind specifically to human CD160, including a light chain variable domain (VL), a chosen sequence defined by SEQ ID No: 14 or SEQ ID No: 13 and a heavy chain variable domain (VH), a sequence chosen from SEQ ID No: 11, SEQ ID No: 25, SEQ ID No: 26, SEQ ID No: 27, SEQ ID No: 28, SEQ ID No: 29 or SEQ ID No: 30, fragments thereof or derivatives thereof.

Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.

Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.

Abstract: Provided herein are methods of treating and preventing hereditary angioedema attack in certain human patient subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 300 mg every two weeks. Exemplary human patient subpopulations include female patients, patients less than 18 years old, between 40 and less than 65 years old, adolescent patients, patients who have had one or more prior laryngeal attacks, patients who have had between 1 and 2, 2 and 3, or more than 3 HAE attacks in the four weeks prior to the first dose of the first treatment period; and/or has received treatment with a C1-inhibitor prior to the first treatment period.

Abstract: Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.

Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Abstract: The present invention provides a dispersion liquid of anion-modified cellulose nanofibers and a composition of anion-modified cellulose nanofibers that are not colored when heated. Specifically, the dispersion liquid contains anion-modified cellulose nanofibers; an anti-coloring agent selected from the group consisting of borate salts and sulfite salts, or combinations thereof in an amount of 1 to 30 mass % based on an absolute dry mass of the anion-modified cellulose nanofibers; and a solvent.

Abstract: Provided is a novel defibration method different from defibration by physical/mechanical pulverization and different from defibration by chemical modification. Provided is a defibration method and a production apparatus each capable of obtaining an intended, fine CNF without chemically modifying the CNF itself and by a treatment for a short time. A method for producing a cellulose nanofiber, the method being a method for continuously obtaining a cellulose nanofiber from raw material cellulose without performing chemical defibration and without performing physical/mechanical defibration in a post-treatment, and comprising mixing subcritical water in a high-temperature/high-pressure state, the subcritical water having a temperature of 180° C. or higher and lower than 370° C. and having a pressure of 5 MPa to 35 MPa, and the raw material cellulose, thereby defibrating the raw material cellulose to obtain a cellulose nanofiber dispersed in water, and a production apparatus for obtaining the cellulose nanofiber.

Abstract: An improved process for the preparation of Sugammadex sodium and its purification process thereof is provided.

Abstract: Embodiments are directed to a catalyst system comprising metal ligand complexes and processes for polyolefin polymerization using the metal ligand complex having the following structure: Formula I

Abstract: A method to make a high melt strength amorphous poly alpha olefin (APAO) includes blending APAO with a free radical initiator using a residence time from 0.1 minutes to 10 minutes at a temperature range from 300 degrees Fahrenheit to 400 degrees Fahrenheit, thereby forming an intermediate. A graftable monomer may then be added to the intermediate in a ratio from 0.1:100 to 2:100 at a temperature range from 225 degrees Fahrenheit to 400 degrees Fahrenheit using a residence time from 0.1 to 20 minutes, thereby forming a functionalized APAO. A multifunctional monomer in an amount ranging from 0.1% to 5% by weight of the functionalized APAO can be added to the functionalized APAO for 0.1 to 20 minutes at 200 to 400 degrees Fahrenheit, thereby forming a cross-linkable APAO. An acid neutralizer may be added to initiate crosslinking, making a crosslinked APAO with various degrees of crosslinking as observed by the changes in the melt viscosity.

Abstract: Polar silane linkers are provided that attach to resins to form silane-functionalized resins. The functionalized resins can be bound to hydroxyl groups on the surface of silica particles to improve the dispersibility of the silica particles in rubber mixtures. Further disclosed are synthetic routes to provide the silane-functionalized resins, as well as various uses and end products that benefit from the unexpected properties of the silane-functionalized resins. Silane-functionalized resins impart remarkable properties on various rubber compositions, such as tires, belts, hoses, brakes, and the like. Automobile tires incorporating the silane-functionalized resins are shown to possess excellent results in balancing the properties of rolling resistance, tire wear, and wet braking performance.

Abstract: A composition comprising an ethylene-based polymer, wherein the ethylene-based polymer comprises the following properties: a) an Mw(abs) from 130,000 to 162,000 g/mol; b) a melt index (I2) from 1.5 to 3.0 g/10 min; c) an ADF LS from 0.350 to 0.450 for molecular weight ?500,000 g/mol.

Abstract: The invention provides a process to form an olefin-based polymer, said process comprising polymerizing at least one olefin in the presence of at least one catalyst system comprising the reaction product of the following: A) at least one cocatalyst; and B) a procatalyst comprising a metal-ligand complex of Formula (I), as described herein:

Abstract: The invention relates to a method of producing amidomethylated vinylaromatic bead polymers.

Abstract: To provide a fluorinated elastic copolymer composition whereby it is possible to obtain a crosslinked rubber article which is excellent in low temperature characteristics and which has sufficient hardness; and a crosslinked rubber article which is excellent in low temperature characteristics and which has sufficient hardness. The fluorinated elastic copolymer composition comprises a fluorinated elastic copolymer having units based on tetrafluoroethylene and units based on CF2?CFORf1 (wherein Rf1 is a C1-10 perfluoroalkyl group), and an organic silicon compound which has a perfluoropolyether chain and at least two polymerizable unsaturated bonds.

Abstract: To provide a fluorinated elastic copolymer and a fluorinated elastic copolymer composition, whereby it is possible to obtain a crosslinked rubber article which has practically sufficient rubber physical properties and which is, at the same time, excellent in low-temperature characteristics; a crosslinked rubber article; and a method for producing a fluorinated elastic copolymer. The fluorinated elastic copolymer comprises units based on tetrafluoroethylene, units based on CF2?CFORf1 (Rf1 is a C1-10 perfluoroalkyl group), units based on CF2?CF(OCF2CF2)n—(OCF2)m?OR f2 (Rf2 is a C1-4 perfluoroalkyl group, n is an integer of from 0 to 3, m is an integer of from 0 to 4, and n+m is an integer of from 1 to 7), and units based on a fluorinated monomer having at least two polymerizable unsaturated bonds.

Abstract: Crosslinked polymers and related compositions and related compositions, electrochemical cells, batteries, methods and systems are described. The crosslinked polymers have at least one redox active monomeric moiety having a redox potential of 0.5 V to 3.0 V with reference to Li/Li+ electrode potential under standard conditions or ?2.54 V to ?0.04 V vs. SHE and has a carbocyclic structure and at least one carbonyl group or a carboxyl group on the carbocyclic structure. The crosslinked polymers also include at least one comonomeric moiety with at least one of the at least one redox active monomeric moiety and/or the at least one comonomeric moiety has a denticity of three to six corresponding to a three to six connected network polymer, and provide stable, high capacity organic electrode materials.

Abstract: Butadiene-isoprene diblock copolymer formed by a block of crystalline polybutadiene (hard block) and by a block of amorphous polyisoprene (soft block). Said butadiene-isoprene diblock copolymer can be advantageously used both in the footwear industry (for example, in the production of shoe soles), and in the production of tires for motor vehicles and/or trucks.

Abstract: A moisture-curable silylated resin is derived from a copolycarbonate diol prepared from diol(s) of specific types.

Abstract: The invention relates to new oil gelling polyurethanes useful for preparing clear gels in organic media (oils, solvents) and to a process for their preparation. The invention also relates to the gels formed from these gelling polyurethanes and to compositions containing them, in particular cosmetic compositions.

Abstract: An elastomeric polymer, comprising (1) a hard segment in the amount of 10% to 60% by weight of the elastomeric polymer, wherein the hard segment includes a urethane, urea or urethaneurea; and (2) a soft segment in the amount of 40% to 90% by weight of the elastomeric polymer. The soft segment comprises (a) at least 2% by weight of the soft segment of at least one polyether macrodiol, and/or at least one polycarbonate macrodiol; and (b) at least 2% by weight of the soft segment of at least one polyisobutylene macrodiol and/or diamine.

Abstract: Provided is a resin composition that has satisfactory impregnability into reinforcing fibers due to low viscosity and small viscosity increase even in an impregnation process performed for a long time. The resin composition being suitable as a matrix resin for a fiber-reinforced composite material for producing a cured molded article that has toughness and fatigue resistance. The resin composition for a fiber-reinforced composite material includes an epoxy resin, an acid anhydride-based curing agent, an imidazole-based curing accelerator, a radically polymerizable monomer, and a radical polymerization initiator as essential components, has a viscosity at 25° C. that falls within a range of 50 mPa·s to 800 mPa·s as measured by an E-type viscometer, and exhibits a viscosity increase ratio of 200% or less after 8 h at 25° C., wherein 50% by mass or more of the acid anhydride-based curing agent is an alicyclic acid anhydride having no olefinic unsaturated bond.